Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PCC0208017 是 MARK3 和 MARK4 的抑制剂,IC50 为 1.8 和 2.01 nM。 PCC0208017 破坏微管动力学并显示出强大的抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,160 | 现货 | ||
2 mg | ¥ 1,720 | 现货 | ||
5 mg | ¥ 2,830 | 现货 | ||
10 mg | ¥ 4,190 | 现货 | ||
25 mg | ¥ 6,720 | 现货 | ||
50 mg | ¥ 9,130 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,180 | 现货 |
产品描述 | PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity. |
体外活性 | PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 (1-5 μM) decreases the phosphorylation of Tau. PCC0208017 (3-21 μM) suppresses the proliferation of glioma cells[1]. |
体内活性 | In C57BL/6 mice bearing murine glioma GL261 xenograft tumor, PCC0208017 (50 and 100 mg/kg; oral) dose-dependently inhibits the growth of xenograft tumors derived with inhibition rates of 56.15% and 70.32%, respectively. PCC0208017 (50 mg/kg; oral) exhibits Cmax and Tmax of 1.36 μg/mL and 0.833 h in plasma and 0.14 μg/mL and 0.833 h in brain[1]. Co-treatment of PCC0208017 (50 mg/kg) significantly enhances the anti-tumor activity of Temozolomide (100 mg/kg) with inhibition rates from 34.15% to 83.5%[1]. |
分子量 | 403.4 |
分子式 | C19H20F3N7 |
CAS No. | 2623158-64-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (278.9 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4789 mL | 12.3946 mL | 24.7893 mL | 61.9732 mL |
5 mM | 0.4958 mL | 2.4789 mL | 4.9579 mL | 12.3946 mL | |
10 mM | 0.2479 mL | 1.2395 mL | 2.4789 mL | 6.1973 mL | |
20 mM | 0.1239 mL | 0.6197 mL | 1.2395 mL | 3.0987 mL | |
50 mM | 0.0496 mL | 0.2479 mL | 0.4958 mL | 1.2395 mL | |
100 mM | 0.0248 mL | 0.1239 mL | 0.2479 mL | 0.6197 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PCC0208017 2623158-64-3 Apoptosis PCC-0208017 PCC 0208017 Inhibitor inhibitor inhibit